Neoplasia/BPH

	Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial. Eur Urol Nagumo Y, Kimura T, Ishikawa H, Sekino Y, Maruo K, Mathis BJ, Kageyama Y, Ushijima H, Kamei J, Yamashita H, Azuma H, Nihei K, Naiki T, Tomita N, Kobayashi Y, Yoshio K, Matsumoto T, Yoshitake T, Osawa T, Nishioka K, Kita Y, Mizowaki T, Hattori K, Tsuzuki T, Hashimoto K, Nishiyama H. PMID: 41548990 [PubMed - as supplied by publisher]
	Adjuvant bacillus Calmette-GuÃ©rin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naÃ¯ve high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study. Int Immunopharmacol Xu T, Wang K, Chen Y, Yu Y, Zhang W, Shen D, Zhang J, Geng J, Peng B, Yan Y, Yao X. PMID: 41548434 [PubMed - as supplied by publisher]
	Two Versus Five-Fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial. Clin Oncol (R Coll Radiol) Romrattaphan R, Dankulchai P, Prasartseree T, Sittiwong W, Thaweerat W, Junlabut S, Nitipitch S. PMID: 41548387 [PubMed - as supplied by publisher]
	Targeting glycolysis in prostate cancer: Molecular mechanisms and therapeutic advances. Biochim Biophys Acta Rev Cancer Zhang J, Zhang T, Song D, Xu D. PMID: 41548699 [PubMed - as supplied by publisher]
	Cellular signaling and radioresistance in prostate cancer. Cell Signal Sosa GA, Crosswhite B, Kirschner AN. PMID: 41548628 [PubMed - as supplied by publisher]
	Current landscape and therapeutic prospects of indole hybrids for prostate cancer treatment: A mini-review. Eur J Med Chem Xu Z, Shi Y, Pan B, Wang H. PMID: 41548295 [PubMed - as supplied by publisher]
	Prognostic Impact of Initial Prostate Specific Antigen Half-Life After Abiraterone Acetate in High-Volume Metastatic Hormone-Sensitive Prostate Cancer: Who May Need Triplet Therapy? Prostate Suzuki K, Ueki H, Wakita N, Okamura Y, Bando Y, Hara T, Terakawa T, Hyodo Y, Chiba K, Teishima J, Miyake H. PMID: 41548191 [PubMed - as supplied by publisher]
	Clinical hurdles for curcumin and piperine nanoparticles in prostate cancer treatment: a bridge too far or a path to clinical reality? Expert Opin Drug Deliv Yakubu J, Tagit O, Pandey AV. PMID: 41548083 [PubMed - as supplied by publisher]
	IRF7 is a novel prognostic biomarker in kidney renal clear cell carcinoma. Sci Rep Fu S, Zhou W, Yin W, Chen Y, Cao L, Chen Y, Xiao Z. PMID: 41547907 [PubMed - as supplied by publisher]
	Generalizable Deep Learning for Prostate Cancer Risk Stratification: Multicenter Study Integrating (18)F-PSMA-1007 PET/CT and mpMRI. Acad Radiol Miao C, Sun H, Yao F, Hong T, Ren Z, Zhuang Y, Lin Q, Bian S, Yang Y, Lin Y. PMID: 41547629 [PubMed - as supplied by publisher]
	Hyaluronic acid-based strategies for prostate cancer therapy. Colloids Surf B Biointerfaces Lan X, Zhou Q, Wang H, Mu Z, Pan L, Yang L, Du Q. PMID: 41547114 [PubMed - as supplied by publisher]
	Treatments and survival outcomes of patients with synchronous and metachronous metastatic bladder cancer: A population-based nationwide cohort study. Cancer Treat Res Commun Richters A, Franken MD, Meijer RP, van der Heijden AG, ProBCI Study Group, van den Berkmortel FWPJ, Aben KKH. PMID: 41546916 [PubMed - as supplied by publisher]
	Inflammation and insulin profiles in men assigned to exercise vs. usual care for prostate cancer: results from the active surveillance exercise (ASX) randomized controlled trial. Cancer Causes Control Pace WA, Olshen A, Wang Y, Kenfield SA, Van Blarigan EL, Graff RE, Cowan J, Wang L, Tenggara I, Lopez K, Encabo K, Jones LW, Panchal N, Cooperberg MR, Carroll PR, Luke A, Pollak M, Chan JM. PMID: 41546786 [PubMed - indexed for MEDLINE]
	Initial results with an absorbable urologic scaffold to mitigate early urinary incontinence following radical prostatectomy: the ARID study. World J Urol Gahan JC, Espino G, Young M, Bodden E, Ferrandino MN. PMID: 41546699 [PubMed - indexed for MEDLINE]
	Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Dermatol Foerster Y, Palaras J, Mayer K, Biedermann T, Persa OD. PMID: 41546605 [PubMed - as supplied by publisher]
	Recent advances and future prospects of immunotherapeutic approaches in prostate cancer. J Transl Med Wang N, Wang C, Cui S, Zhao K, Zhang J, Zhang L, Jia Y, Kong F. PMID: 41546087 [PubMed - as supplied by publisher]
	Artificial intelligence in bladder cancer management: a narrative review of diagnostic and surgical advances and current limitations. Expert Rev Anticancer Ther Salzano G, Digiacomo A, Dello Stritto G, Orsini A, De Archangelis R, Cicchetti R, Lannutti P, Ferretti S, Schips L, Marchioni M. PMID: 41545941 [PubMed - as supplied by publisher]
	Risk-Stratified Gleason Upgrading in ISUP Grade Group 1 Prostate Cancer: Combined Analysis of TMPRSS2-ERG, PTEN, Ki-67, and MRI-Derived Apparent Diffusion Coefficient Values. Int J Urol Alkan Vur, , Vur, Ya, Çelen S, Duran MB. PMID: 41545857 [PubMed - indexed for MEDLINE]
	From mechanisms to therapy: the role of tertiary lymphoid structures in bladder cancer. World J Surg Oncol Yang J, Li X, Xie H, Guo J, Wang J, Lin C. PMID: 41545849 [PubMed - as supplied by publisher]
	Circulating tumour cells as a window into lethality in prostate cancer. Nat Rev Urol Abusamra SM, Anbarasan T, Cotton DT, Ranasinha NMS, Barber R, Bridge S, Smith C, Figiel S, Yin W, Davis JJ, Salami SS, Hamdy FC, Bryant RJ, Lu YJ, Mills IG, Edwards CM, Morgan TM, Lamb AD. PMID: 41545704 [PubMed - as supplied by publisher]

Articles 1 - 20 / 184738

Page 1 of 9237



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy